Home > Dermatology > EADV 2019 > Late-Breaking News > Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Presented By
Prof. Pascal Joly, Rouen University Hospital, France
Conference
EADV 2019
Trial
Phase 3, PEMPHIX, Ritux 3
Pemphigus vulgaris patients had a 5 times greater likelihood of achieving a complete remission when treated with rituximab compared mycophenolate mofetil (MMF). In addition, the anti-CD20 monoclonal antibody had a superior safety profile. Prof. Pascal Joly (Rouen University Hospital, France) presented the results of the randomised, clinical, phase 3 PEMPHIX trial, which compared rituximab head-to-head with MMF for the treatment of pemphigus vulgaris [1]. Although MMF is commonly used as a corticosteroid-sparing drug in patients with pemphigus vulgaris, its efficacy has never been proven in a clinical trial. In contrast, rituximab was approved earlier this year by the US authorities and the European Commission for the treatment of adults with moderate-to-severe pemphigus vulgaris. It is the first approved biologic, and therefore a major advancement in the treatment ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on